What is Kitamass?
Kitamass is a nonsteroidal anti-inflammatory drug (NSAID). Kitamass works by reducing hormones that cause inflammation and pain in the body.
Kitamass is used short-term (5 days or less) to treat moderate to severe pain.
Kitamass may also be used for purposes not listed in this medication guide.
Kitamass indications
Carefully consider the potential benefits and risks of Kitamass Tromethamine and other treatment options before deciding to use Kitamass. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
Acute Pain in Adult Patients
Kitamass Tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM dosing of Kitamass Tromethamine, and oral Kitamass Tromethamine is to be used only as continuation treatment, if necessary.
The total combined duration of use of Kitamass Tromethamine injection and oral Kitamass Tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses. Patients should be switched to alternative analgesics as soon as possible, but Kitamass Tromethamine therapy is not to exceed 5 days.
Kitamass Tromethamine injection has been used concomitantly with morphine and meperidine and has shown an opioid-sparing effect. For breakthrough pain, it is recommended to supplement the lower end of the Kitamass Tromethamine injection dosage range with low doses of narcotics prn, unless otherwise contraindicated. Kitamass Tromethamine injection and narcotics should not be administered in the same syringe.
How should I use Kitamass?
Use Kitamass spray as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Kitamass spray comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Kitamass spray refilled.
- Do not take Kitamass spray by mouth. Use in your nose only.
- Before you use each bottle for the first time, you must prime it. Remove the clear plastic cover and the blue plastic safety clip. Hold the bottle at arm's length away from you. Using your index and middle fingers on the top of the bottle and your thumb on the bottom of the bottle, press down evenly and release the pump 5 times. The bottle is now ready to use.
- To use this nose spray, gently blow your nose. Sit up straight or stand and tilt your head forward slightly. Place the tip of the spray container into the nose. Be sure to point the container away from the center of your nose. Breathe gently through the nostril and squeeze the spray container. If your dose requires 2 sprays, repeat the process for your other nostril. Replace the clear plastic cover after each use.
- Do NOT use Kitamass spray for more than 5 days. Kitamass spray is not for the treatment of mild to moderate or chronic pain (eg, headache).
- Avoid contact with the eyes. If you get Kitamass spray in your eyes, rinse it out with water. If eye irritation persists for more than 1 hour, contact your doctor.
- Each bottle contains 1 day's supply of Kitamass spray. Discard each bottle within 24 hours of opening it, even if it still contains some unused medicine.
- If you miss a dose of Kitamass spray and you are taking it regularly, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Kitamass spray.
Uses of Kitamass in details
Use: Labeled Indications
Pain, moderate to moderately severe: Short-term (up to 5 days) management of moderate to moderately severe pain in adults that requires analgesia at the opioid level.
Off Label Uses
Migraine
Data from a prospective, randomized, double-blind, double-dummy, placebo and active comparator, crossover, non-inferiority trial suggests that intranasal Kitamass may be beneficial for acute abortive treatment of migraine in patients with a history of episodic migraines for at least 1 year.
Kitamass description
A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Kitamass is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
Kitamass dosage
Carefully consider the potential benefits and risks of Kitamass tromethamine tablets and other treatment options before deciding to use Kitamass tromethamine tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. In adults, the combined duration of use of IV or IM dosing of Kitamass tromethamine and Kitamass tromethamine tablets is not to exceed 5 days. In adults, the use of Kitamass tromethamine tablets is only indicated as continuation therapy to IV or IM dosing of Kitamass tromethamine.
Transition from IV or IM dosing of Kitamass tromethamine (single- or multiple-dose) to multiple-dose Kitamass tromethamine tablets:
Patients age 17 to 64: 20 mg PO once followed by 10 mg q4 to 6 hours prn not > 40 mg/day
Patients age ≥ 65, renally impaired, and/or weight < 50 kg (110 lbs): 10 mg PO once followed by 10 mg q4 to 6 hours prn not > 40 mg/day
Note:
Oral formulation should not be given as an initial dose.
Use minimum effective dose for the individual patient.
Do not shorten dosing interval of 4 to 6 hours.
Total duration of treatment in adult patients: the combined duration of use of IV or IM dosing of Kitamass tromethamine and Kitamass tromethamine tablets is not to exceed 5 days.
The following table summarizes Kitamass tromethamine tablet dosing instructions in terms of age group:
| Patient Population | Kitamass Tromethamine Tablets (following IV or IM dosing of Kitamass tromethamine) |
| Age < 17 years | Oral not approved |
| Adult Age 17 to 64 years | 20 mg once, then 10 mg q4 to 6 hours prn not > 40 mg/day |
| Adult Age ≥ 65 years, renally impaired, and/or weight < 50 kg | 10 mg once, then 10 mg q4 to 6 hours prn not > 40 mg/day |
Kitamass interactions
See also:
What other drugs will affect Kitamass?
Kitamass slightly reduces the plasma protein-binding of warfarin. In vitro studies indicate that at therapeutic concentration of salicylate, the binding of Kitamass reduces from approximately 99.2-97.5%; representing a potential 2-fold increase in unbound plasma Kitamass levels. Kitamass has been reported to reduce the diuretic response to furosemide in normovolemic individuals by approximately 20%.
Concomitant administration of Kitamass and probenecid results in decreased clearance of Kitamass and significant increase in Kitamass plasma levels (approximately 3-fold increase), and there is an increase of approximately 2-fold in terminal half-life.
Increase in plasma lithium concentration due to inhibition of renal lithium clearance has been reported with some NSAIDs. There have been some reports of increased lithium plasma levels with Kitamass also.
There have been reports of a possible interaction of Kitamass and nondepolarizing muscle relaxants, which lead to apnea. Concomitant use of Kitamass and angiotensin-converting enzyme inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients.
Very few cases of seizure have been reported with concomitant use of Kitamass and antiepileptic drugs (phenytoin, carbamazepine). There have been reports of hallucinations when Kitamass is concomitantly used with psychoactive drugs (fluoxetine, thiothixene, alprazolam).
Laboratory Tests: Kitamass inhibits platelet aggregation and may prolong bleeding time.
Food: Food reduces the rate but not the extent of absorption.
Kitamass side effects
See also:
What are the possible side effects of Kitamass?
Applies to Kitamass ophthalmic: ophthalmic solution
In addition to its needed effects, some unwanted effects may be caused by Kitamass ophthalmic. In the event that any of these side effects do occur, they may require medical attention.
Major Side Effects
You should check with your doctor immediately if any of these side effects occur when taking Kitamass ophthalmic:
More common:
- Itching, redness, tearing, or other sign of eye irritation not present before use of this medicine or becoming worse during use
- redness of the clear part of the eye
- sensitivity to light
- swelling of the eye
- tearing
- throbbing pain
- Blurred vision or other change in vision
- eye irritation or redness
Minor Side Effects
Some of the side effects that can occur with Kitamass ophthalmic may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
More common:
- Stinging or burning of the eye when medicine is applied
- Dry eyes
- headache
Kitamass contraindications
See also:
What is the most important information I should know about Kitamass?
Kitamass Tromethamine is contraindicated in patients with previously demonstrated hypersensitivity to Kitamass Tromethamine.
Kitamass Tromethamine is contraindicated in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding.
Kitamass Tromethamine should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.
Kitamass Tromethamine is contraindicated as prophylactic analgesic before any major surgery.
Kitamass Tromethamine is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Kitamass Tromethamine is contraindicated in patients with advanced renal impairment or in patients at risk for renal failure due to volume depletion.
Kitamass Tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine musculature, thus increasing the risk of uterine hemorrhage.
Kitamass Tromethamine inhibits platelet function and is, therefore, contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding.
Kitamass Tromethamine is contraindicated in patients currently receiving aspirin or NSAIDs because of the cumulative risks of inducing serious NSAID-related adverse events.
The concomitant use of Kitamass Tromethamine and probenecid is contraindicated.
The concomitant use of Kitamass Tromethamine and pentoxifylline is contraindicated.
Kitamass Tromethamine injection is contraindicated for neuraxial (epidural or intrathecal) administration due to its alcohol content.
Active ingredient matches for Kitamass:
Ketorolac in Peru.
List of Kitamass substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Kirtolac (Taiwan) | |
| Kirtolac 0.5 % x 5 mL | |
| Klenac (Argentina) | |
| KOLAC | |
| KOLAC EYE DROPS 1 packet / 5 ML eye drop each (Medivision Pharm) | $ 0.84 |
| Kolac 0.5% w/v Eye Drop (Medivision Pharm) | $ 0.84 |
| Kop (Bangladesh, Taiwan) | |
| KOP 30 mg/1 mL x 1 mL | |
| KOP 30 mg/1 mL x 2 mL | |
| Koprak (Mexico) | |
| Kortezor (Philippines) | |
| Kortezor / amp 30 mg/1 mL x 10's (Biomedis) | $ 19.90 |
| Kotonic (Bangladesh) | |
| Koxalgen (Mexico) | |
| Kroller (Italy) | |
| Ktolac (Taiwan) | |
| Ktolac 30 mg/1 mL x 1 mL | |
| Laborac | |
| Laborac 0.5% w/v EYE DPS / 5ml | $ 0.30 |
| Lacdol-S (Mexico) | |
| Lacomin (Mexico) | |
| Lactopain (Indonesia) | |
| Lactopain / amp 30 mg/1 mL x 1 mL x 5's (Lapi) | $ 16.12 |
| Lactor (Indonesia) | |
| Lactor 30 mg/1 mL x 1 mL x 6's (Phapros) | $ 18.00 |
| Landaco (Mexico) | |
| Lantipain (Indonesia) | |
| Lantipain 10 mg/1 mL x 6's (Landson) | $ 12.03 |
| Lantipain 30 mg/1 mL x 6's (Landson) | $ 17.98 |
| Laston (Taiwan) | |
| Laston 30 mg/1 mL x 1 mL | |
| Latorec (Indonesia) | |
| Legrace (Brazil) | |
| Lenaken (Mexico) | |
| Lixidol (Italy) | |
| LOKAT | |
| LOKAT 0.4% EYE DROPS 1 packet / 5 ML eye drop each (Jawa Pharmaceuticals Pvt Ltd) | $ 0.68 |
| Lokat 0.4% Eye Drop (Jawa Pharmaceuticals Pvt Ltd) | $ 0.68 |
| Lokefar (Mexico) | |
| Capsule; Oral; Ketorolac Tromethamine 10 mg | |
| Capsule; Oral; Ketorolac Tromethamine 20 mg | |
| Capsules; Oral; Ketorolac Tromethamine 10 mg | |
| Capsules; Oral; Ketorolac Tromethamine 20 mg | |
| Lopadol (Bangladesh) | |
| Lorotec (Mexico) | |
| Lorotec F (Mexico) | |
| Tablet; Sublingual; Ketorolac Tromethamine 30 mg | |
| Tablets; Sublingual; Ketorolac Tromethamine 30 mg | |
| Lupelac (Bangladesh) | |
| Madredol (Georgia) | |
| Mar-Ketorolac (Canada) | |
| Marolac (Philippines) | |
| Marolac 25mg x 1mL INJ / 3ml (Spinogen) | $ 0.10 |
| MAROLAC inj 25 mg x 1 mL x 3ml (Spinogen) | $ 0.10 |
| Matolac (Indonesia) | |
| Matolac 10 mg x 5's (Mahakam Beta Farma) | $ 10.07 |
| Matolac 30 mg x 5's (Mahakam Beta Farma) | $ 14.88 |
See 936 substitutes for Kitamass | |
References
- PubChem. "ketorolac". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "ketorolac". http://www.drugbank.ca/drugs/DB00465 (accessed September 17, 2018).
- MeSH. "Cyclooxygenase Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Kitamass are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Kitamass. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet1 consumer reported age
| Users | % | ||
|---|---|---|---|
| 46-60 | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
